Capricor Therapeutics CAPR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | $0-100% | $11.13M-16.9% | $13.39M-22.9% | $17.36M-22.0% | ||
| $92.92M+10.0% | $84.45M+11.3% | $75.88M+12.7% | $67.33M+16.5% | $57.78M+15.6% | ||
| $27.02M+14.1% | $23.69M+8.0% | $21.94M+12.6% | $19.47M+15.5% | $16.86M+13.4% | ||
| $119.93M+10.9% | $108.14M+10.6% | $97.81M+12.7% | $86.8M+16.3% | $74.64M+15.1% | ||
| -$119.93M-10.9% | -$108.14M-24.8% | -$86.68M-18.1% | -$73.41M-28.2% | -$57.28M-34.6% | ||
| —— | —— | $4.69M+36.7% | $3.43M+54.9% | $2.22M+5.7% | ||
| —— | —— | —— | —— | -$54.74M-35.3% | ||
| —— | —— | —— | —— | $1.2K-25.0% | ||
| -$114.59M-9.1% | -$105.04M-28.1% | -$81.99M-17.2% | -$69.98M-27.1% | -$55.06M-36.1% | ||
| -$2.32-2.7% | -$2.26-29.1% | -$1.75-10.1% | -$1.59-16.1% | -$1.37-19.1% | ||
| -$117.91M-11.0% | -$106.25M-25.1% | -$84.92M-18.3% | -$71.78M-28.7% | -$55.78M-35.6% | ||
| -$119.93M-10.9% | -$108.14M-24.8% | -$86.68M-18.1% | -$73.41M-28.2% | -$57.28M-34.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Capricor Therapeutics profitable?
- Capricor Therapeutics is not currently profitable: it reported a net loss of $114.6M over the trailing twelve months, a -736.6% net margin.
- What is Capricor Therapeutics's earnings per share?
- Capricor Therapeutics's diluted EPS over the trailing twelve months is $-2.32.
- Where does Capricor Therapeutics's income statement data come from?
- Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.